Cargando…
Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence
Gastric cancer remains one of the leading cancers in the world with a high mortality, particularly in East Asia. Helicobacter pylori infection accounts for the majority of the noncardia gastric cancers by triggering gastric inflammation and subsequent neoplastic progression. Eradication of H. pylori...
Autores principales: | Cheung, Ka Shing, Leung, Wai K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415482/ https://www.ncbi.nlm.nih.gov/pubmed/30886648 http://dx.doi.org/10.1177/1756284819834511 |
Ejemplares similares
-
Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after Helicobacter pylori eradication
por: Cheung, Ka Shing, et al.
Publicado: (2018) -
Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2021) -
Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
por: Thong, Benjamin Ka Seng, et al.
Publicado: (2019) -
Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy
por: Holmberg, Dag, et al.
Publicado: (2022) -
The risks of long-term use of proton pump inhibitors: a critical
review
por: Jaynes, Megan, et al.
Publicado: (2018)